IL6 and congenital rubella syndrome: In pediatric patients receiving CAR T-cell treatment for relapsed and refractory B-cell malignancies, CRS is a common serious AE, which is successfully mitigated by treatment with the IL-6 inhibitor tocilizumab.89,105,106 Given this observation, the inclusion of anti-inflammatory drugs in immunotherapy treatment backbones should also be explored as a therapeutic option for treating CRS in aged patients.